Compounded Fentanyl-Ropivacaine Epidural Injection Recalled Due to Sterility Assurance Concerns
QuVa Pharma is recalling 1,765 cassettes of compounded epidural injection due to lack of sterility assurance. The affected lots were distributed nationwide to institutional and office locations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a high-risk injectable product (epidural injection) due to lack of sterility assurance. The source text does not report any associated illnesses, injuries, or deaths, placing this as a risk-of-harm scenario without reported injury.
Plain-English summary
QuVa Pharma, Inc. is recalling 1,765 cassettes of fentaNYL Citrate PF 200 mcg/100 mL / 0.2% ROPivacaine HCl 200 mg/100 mL in 100 mL NS Yellow CADD FSFF injection for epidural use. This is a compounded product intended for institutional or office use only.
The recall was issued due to lack of assurance of sterility. The affected lots are Lot 10140303 (expiring 04/14/2025), Lots 10140867 and 10140868 (expiring 04/24/2025), and Lot 10140965 (expiring 04/28/2025). These products were distributed nationwide.
Healthcare providers who have received the affected lots should contact QuVa Pharma, Inc. for further instructions regarding the recalled product.
The recalled product
- Product
- fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 mL (2 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Su
- Manufacturer
- QuVa Pharma, Inc.
- Category
- Drug — Injectable / Compounded
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot
- expiry: Lot 10140303
- exp 04/14/2025
- Lots 10140867
- 10140868
- exp 04/24/2025
- Lot 10140965
- exp 04/28/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27